Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRABiotechnology
-$0.10 today
- Market cap
- $69.21M
- Beta
- 2.76
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$1.24
Volume 1.50M
Average 2.02M
NMRA Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Neumora Therapeutics, Inc. Common StockNASDAQ: NMRA
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity falls 69.0% from a year ago
Total equity stood at $70.68M at the end of Q1 FY2026, down 69.0% from a year earlier and down 32.0% from the prior quarter.
Context
- Total equity amounted to 45.9% of total assets at the end of Q1 FY2026, down 43.0 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -69.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 103.87M USD
- Year-over-year change
- -63.8%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 103.87M | -63.8% |
| FY2024 | 2024-12-31 | 287.06M | -38.8% |
| FY2023 | 2023-12-31 | 469.08M | +205.0% |
| FY2022 | 2022-12-31 | (446.85M) | -37.4% |
| FY2021 | 2021-12-31 | (325.22M) | — |
Total Equity vs competitors
How NMRA compares with its peers on the latest reported figures
- NMRA's Mar 2026 total equity of $70.68M is the 8th highest of the 10 companies compared; the peer median is $312.62M.
- Its year-over-year change of -69.0% is the 9th highest of 10, against a peer median of -3.8%.
- Total equity amounts to 45.9% of total assets for NMRA, versus a peer median of 80.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $554.32M | -25.1% | +31.1% | 85.0% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $452.16M | -6.8% | — | 80.7% |
| Mar 2026 | $451.84M | -3.8% | +29.8% | 88.1% | |
| Mar 2026 | $333.3M | +45.9% | +20.6% | 96.1% | |
| Mar 2026 | $312.62M | -28.6% | -23.3% | 89.3% | |
| Mar 2026 | $202.86M | +64.9% | -2.8% | 75.5% | |
| Mar 2026 | $108.83M | -70.7% | -15.8% | 20.6% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $70.68M | -69.0% | — | 45.9% |
| Mar 2026 | -$63.33M | +70.3% | — | 22.1% | |
| Mar 2026 | -$216.38M | +9.2% | — | 74.2% | |
| Peer median (excluding NMRA) | $312.62M | -3.8% | +8.9% | 80.7% | |
Competitors are the stored peer set for NMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 409.25M | 240.94M | 374.04M | 142.15M | 182.53M |
| Short-term Investments | 0 | 130.94M | 79.94M | 165.43M | 0 |
| Net Receivables | 200K | 919K | 939K | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 125K | 50K | 0 | 6.48M | 8.01M |
| Total Current Assets | 415.6M | 387.96M | 478.28M | 314.06M | 190.54M |
| Property, Plant & Equipment (Net) | 4.04M | 10.64M | 6.86M | 2.92M | 457K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 23.51M | 9.85M | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 9.65M | 4.13M | 1.21M | 0 | 53K |
| Total Non-current Assets | 13.69M | 38.28M | 17.92M | 2.92M | 510K |
| Total Assets | 429.3M | 426.23M | 496.2M | 316.97M | 191.05M |
| Account Payables | 1.64M | 7.15M | 337K | 3.31M | 3.38M |
| Short-term Debt | 0 | 0 | 0 | 0 | 284K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 8.13M | 10.04M | 10.15M | 10.11M | 28.79M |
| Total Current Liabilities | 23.28M | 23.7M | 25.11M | 29.89M | 32.45M |
| Long-term Debt | 0 | 0 | 0 | 0 | 193K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 730.24M | 844.32M | 155K | 22K | 54.53M |
| Total Non-current Liabilities | 731.24M | 849.39M | 2.01M | 22K | 54.73M |
| Total Liabilities | 754.52M | 873.08M | 27.12M | 29.91M | 87.18M |
| Common Stock | 3K | 3K | 16K | 16K | 17K |
| Retained Earnings | (336.61M) | (467.51M) | (703.43M) | (947.22M) | (1.18B) |
| Accumulated OCI | 0 | (774K) | (76K) | 62K | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (325.22M) | (446.85M) | 469.08M | 287.06M | 103.87M |
| Total Debt | 2.05M | 8.44M | 5.23M | 1.85M | 477K |
| Net Debt | (407.2M) | (232.5M) | (368.81M) | (140.3M) | (182.05M) |
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
Intrinsic Alpha fair value
Locked
Current Price
$0.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.